对于患有型菌症的儿童的治疗方法的变化
Chiara Michienzie1, John Galgiani2,3, Sean P Fitzwater4
1Department of Pediatrics, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
Pediatrics
|March 12, 2026
概括
儿科皮小菌病 (CM) 管理表现出差异性,但结果通常是好的. 在没有抗真菌药物治疗或观察后,真菌感染的复发在儿童中很罕见.
科学领域:
- 儿童传染病 儿童传染病
- 菌类学 菌类学是指菌类学.
- 流行病学 流行病学
背景情况:
- 与成年人相比,小儿科人群中对皮小菌病 (CM) 的了解较少.
- 凯泽永久南加州 (KPSC) 系统提供了一个独特的环境来研究儿科CM,因为它位于一个特有地区.
研究的目的:
- 在大量儿童中描述了菌菌的诊断,治疗和结果.
- 确定儿科CM临床决策中的模式和变异性.
主要方法:
- 对2015年至2021年期间被诊断患有CM的儿科患者 (≤17岁) 病历的回顾性审查.
- 数据提取包括人口统计,症状,诊断测试和治疗细节.
主要成果:
- 确定了209例儿科CM病例,每10万名儿童中发生率为3.3例.
- 发烧,咳和皮疹是常见的症状;散布的CM发生在4.8%的患者中.
- 抗真菌治疗或没有抗真菌药物的观察后的复发很少 (分别为1.2%和2.1%).
结论:
- 在儿科皮小菌病的临床管理中存在显著的变化.
- 没有抗真菌治疗的观察通常是成功的,复发率很低.
- 症状随访对于管理儿科CM至关重要,而无症状患者的血清学检测结果很少改变管理.
相关概念视频
Cystic Fibrosis: Management
601
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
601
Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
COPD: Management Using Bronchodilators and Corticosteroids
1.0K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.0K
Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K
Pulmonary Tuberculosis V
728
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
728
Pneumonia IV: Management
999
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
999


